var data={"title":"Ivermectin (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ivermectin (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/498390?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ivermectin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Ivermectin (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=ivermectin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ivermectin (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841863\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Stromectol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13853113\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anthelmintic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anti-ectoparasitic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13853122\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ivermectin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Ivermectin (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Following the indication-specific dosing information are weight-band dosing tables to assist with calculation and rounding of doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ascariasis due to <i>Ascaris lumbricoides </i>(roundworm):</b> Limited data available: Children &ge;15 kg and Adolescents: Oral: 150 to 200 mcg/kg/dose as a single dose (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Cutaneous larva migrans</b></i>\n      <b> (dog and cat hookworm)</b>\n      <b>:</b> Limited data available: Children &ge;15 kg and Adolescents: Oral: 200 mcg/kg once daily for 1 to 2 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Filariasis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Mansonella ozzardi</i>: Limited data available: Children &ge;15 kg and Adolescents: Oral: 200 mcg/kg/dose as a single dose (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Mansonella streptocerca</i>\n      <i>:</i> Limited data available: Children &ge;15 kg and Adolescents: Oral: 150 mcg/kg/dose as a single dose (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Wuchereria bancrofti</i>: Limited data available: Children &ge;15 kg and Adolescents: Oral: 200 mcg/kg/dose as a single dose given in combination with albendazole (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gnathostomiasis due to <i>Gnathostoma spinigerum</i></b>: Limited data available: Children &ge;15 kg and Adolescents: Oral: 200 mcg/kg once daily for 2 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Onchocerciasis</b>\n      <b> (<i>Onchocerca volvulus, </i>river blindness):</b> Children &ge;15 kg and Adolescents: Oral: 150 mcg/kg/dose as a single dose; may repeat every 6 to 12 months until asymptomatic; for prevention of blindness due to ocular onchocerciasis, doses repeated every 3 to 12 months are suggested (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pediculosis (lice):</b> Limited data available: <b>Note:</b> Ivermectin is not ovicidal; therefore, repeat doses are necessary to eradicate infestation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Head lice: Children &ge;15 kg and Adolescents: Oral: 400 mcg/kg/dose on days 1 and 8 (Chosidow 2010) <b>or</b> 200 mcg/kg/dose repeated once after 10 days (Jones 2003) have been shown to be effective (AAP [Devore 2015]; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pubic lice: Children &ge;15 kg and Adolescents: Oral: 250 mcg/kg/dose for 2 doses administered 14 days apart (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Scabies due to <i>Sarcoptes scabiei</i>:</b> Limited data available: Children &ge;15 kg and Adolescents: Oral: 200 mcg/kg/dose for 2 doses administered at least 7 days apart (<i>Red Book</i> [AAP 2015]); others suggest doses be separated by 14 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Strongyloidiasis</b>: Children &ge;15 kg and Adolescents: Oral: 200 mcg/kg once daily for 2 days (<i>Red Book</i> [AAP 2015]). Immunocompromised patients or patients with disseminated disease may need to repeat therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Trichuriasis due to <i>Trichuris trichiura </i>(whipworm):</b> Limited data available: Children &ge;15 kg and Adolescents: Oral: 200 mcg/kg once daily for 3 days (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Weight-band dosing tables: </b></p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Weight-Band Dosing to Provide ~150 mcg/kg</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Patient Weight</p>\n            <p style=\"text-indent:0em;\">(kg)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Single Oral Dose</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 25</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">26 to 44</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">45 to 64</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">65 to 84</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;85</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">150 mcg/kg</p></td></tr></tbody></table>\n    \n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Weight-Band Dosing to Provide ~200 mcg/kg</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Patient Weight</p>\n            <p style=\"text-indent:0em;\">(kg)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Single Oral Dose</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 24</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25 to 35</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">36 to 50</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">51 to 65</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">66 to 79</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 mg</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;80</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200 mcg/kg</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b> Onchocerciasis:</b> Oral: 150 mcg/kg as a single dose; retreatment may be required every 3 to 12 months until asymptomatic</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Strongyloidiasis, intestinal:</b> Oral: 200 mcg/kg/day for 1 to 2 days (CDC 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841927\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stromectol: 3 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 3 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841865\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13853123\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer on an empty stomach with water</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841896\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at temperatures below 30&deg;C (86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13853114\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of intestinal strongyloidiasis (FDA approved in pediatric patients &ge;15 kg and adults); treatment of onchocerciasis due to the immature form of <i>Onchocerca volvulus</i> (FDA approved in pediatric patients &ge;15 kg and adults). Has also been used for the treatment of other parasitic infections including but not limited to: <i>Ancylostoma braziliense</i>, <i>Ascaris lumbricoides</i>, <i>Gnathostoma spinigerum</i>, <i>Mansonella ozzardi</i>, <i>Mansonella streptocerca</i>, <i>Pediculus humanus capitis</i>, <i>Pediculus humanus corporis</i>, <i>Phthirus pubis</i>, <i>Trichuris trichiura</i>, <i>Sarcoptes scabiei</i>, and <i>Wuchereria</i><i> bancrofti</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841884\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Facial edema, orthostatic hypotension, peripheral edema, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermatological reaction (Mazzotti reaction, associated with onchocerciasis; includes edema, urticarial rash), pruritus (includes Mazzotti reaction, associated with onchocerciasis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Decreased white blood cell count, eosinophilia, increased hemoglobin, lymphadenitis (Mazzotti reaction, associated with onchocerciasis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia (Mazzotti reaction, associated with onchocerciasis), synovitis (Mazzotti reaction, associated with onchocerciasis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (Mazzotti reaction, associated with onchocerciasis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening): Abdominal distention, abdominal pain, abnormal gait, abnormal sensation in eyes, anemia, anorexia, anterior uveitis, ataxia, back pain, brain disease (rare; associated with loiasis), chest discomfort, chorioretinitis, coma, confusion, conjunctival hemorrhage (associated with onchocerciasis), conjunctivitis, constipation, drowsiness, dyspnea, exacerbation of asthma, eye redness, eyelid edema, fatigue, fecal incontinence, headache, hepatitis, hypotension, increased serum bilirubin, keratitis, lethargy, leukopenia, mental status changes, myalgia, neck pain, posterior uveitis, seizure, skin rash, Stevens-Johnson syndrome, stupor, temporary vision loss, toxic epidermal necrolysis, tremor, urinary incontinence, urticaria, vertigo, vomiting, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841879\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ivermectin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841880\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous/systemic reactions: Data have shown that antihelmintic drugs like ivermectin may cause cutaneous and/or systemic reactions (Mazzoti reaction) of varying severity including ophthalmological reactions in patients with onchocerciasis. These reactions are probably due to allergic and inflammatory responses to the death of microfilariae. Patients treated with ivermectin for onchocerciasis may experience these reactions. Treatment of severe Mazzoti reactions is not definitive, but includes supportive care (eg, hydration and/or parenteral corticosteroids) to treat postural hypotension. Antihistamines and/or aspirin have been used for most mild to moderate reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull;  Loiasis: Pretreatment assessment and post-treatment follow up for <i>Loa loa</i> infection is recommended in any patient with significant exposure to endemic areas (West and Central Africa); serious and/or fatal encephalopathy has been reported (rarely) during treatment in onchocerciasis patients with concomitant loiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunocompromised patients: Repeated treatment may be required in immunocompromised patients (eg, HIV); control of extraintestinal strongyloidiasis may necessitate suppressive (once monthly) therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <i>Onchocerca volvulus:</i> Ivermectin has no activity against adult <i>O. volvulus</i> parasites.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26023254\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid use or use with extreme caution in pediatric patients &lt;2 years or &lt;15 kg; the American Academy of Pediatrics (AAP) cautions against using ivermectin in these patients due to a less developed blood-brain barrier compared to older pediatric patients and an increased risk for CNS effects (ie, encephalopathy); monitor patients closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841889\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841887\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=83316&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Azithromycin (Systemic): May increase the serum concentration of Ivermectin (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Ivermectin (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841894\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Bioavailability is increased 2.5-fold when administered following a high-fat meal. Management: Administer on an empty stomach.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841873\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841874\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Although use in pregnancy is likely low risk, other agents are currently recommended for the treatment of pediculosis pubis or scabies in pregnant women (CDC [Workowski 2015]). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13853124\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Skin and eye microfilarial counts, periodic ophthalmologic exams; follow up stool examinations; blood pressure (mainly orthostatic hypotension has been observed); periodic liver function tests</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841897\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ivermectin is a semisynthetic anthelminthic agent; it binds selectively and with strong affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to increased permeability of cell membranes to chloride ions then hyperpolarization of the nerve or muscle cell, and death of the parasite.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841899\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Well absorbed (Gonzalez Canga 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 3.1 to 3.5 L/kg (healthy males); high concentration in the liver and adipose tissue; does not readily cross the blood-brain barrier (Gonzalez Canga 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~93% primarily to albumin (Gonzalez Canga 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4 (major), CYP2D6 (minor), and CYP2E1 (minor)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: ~4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces; urine (&lt;1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841930\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ivermectin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (20): $99.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Stromectol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (20): $111.66</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841933\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ascapil (IN);</li>\n      <li>Detebencil (AR);</li>\n      <li>Ectin (IN);</li>\n      <li>Ivactin (BD);</li>\n      <li>Iver P (AR);</li>\n      <li>Ivermect (IN);</li>\n      <li>Ivertal (AR);</li>\n      <li>Iverx (CL);</li>\n      <li>Ivexterm (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Ivomec (CH);</li>\n      <li>Kaonol (CL, PE);</li>\n      <li>Kilox (CO, CR, DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Leverctin (BR);</li>\n      <li>Maikeding (CN);</li>\n      <li>Mectizan (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, VN, ZA, ZM, ZW);</li>\n      <li>Quamox (PE);</li>\n      <li>Quanox Gotas (CO);</li>\n      <li>Revectina (BR);</li>\n      <li>Sanifer (UY);</li>\n      <li>Scabo (BD);</li>\n      <li>Securo (AR);</li>\n      <li>Stromectol (AU, BB, FR, GR, NL, NZ, SG, VN);</li>\n      <li>Veratin (BD);</li>\n      <li>Vermectil (BR);</li>\n      <li>Vermectin (TH);</li>\n      <li>Vermokill (PY);</li>\n      <li>Yvermil (PY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds; <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. Parasites - <i>Strongyloides.</i> August 2016. Available at <a href=\"https://www.cdc.gov/parasites/strongyloides/health_professionals/index.html\" target=\"_blank\">https://www.cdc.gov/parasites/strongyloides/health_professionals/index.html</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chosidow O, Giraudeau B, Cottrell J, et al, &quot;Oral Ivermectin Versus Malathion Lotion for Difficult-to-Treat Head Lice,&quot; <i>N Engl J Med</i>, 2010, 362(10):896-905.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/20220184/pubmed\" target=\"_blank\" id=\"20220184\">20220184</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Devore CD, Schutze GE, Council on School Health and Committee on Infectious Diseases, American Academy of Pediatrics. Head lice. <i>Pediatrics</i>. 2015;135(5):e1355-1365.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/25917986/pubmed\" target=\"_blank\" id=\"25917986\">25917986</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foucault C, Ranque S, Badiaga S, et al, &quot;Oral Ivermectin in the Treatment of Body Lice,&quot; <i>J Infect Dis</i>, 2006, 193(3):474-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/16388498/pubmed\" target=\"_blank\" id=\"16388498\">16388498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gonz&aacute;lez Canga A, Sahag&uacute;n Prieto AM, Diez Li&eacute;bana MJ, et al, &quot;The Pharmacokinetics and Interactions of Ivermectin in Humans - A Mini-Review,&quot; <i>AAPS J</i>, 2008, 10(1):42-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/18446504/pubmed\" target=\"_blank\" id=\"18446504\">18446504</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ivermectin tablets [prescribing information]. Parsippany, NJ: Edenbridge Pharmaceuticals, LLC; January 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones KN and English JC 3rd, &quot;Review of Common Therapeutic Options in the United States for the Treatment of Pediculosis Capitis,&quot; <i>Clin Infect Dis</i>, 2003, 36(11):1355-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/12766828/pubmed\" target=\"_blank\" id=\"12766828\">12766828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-pediatric-drug-information/abstract-text/26042815 /pubmed\" target=\"_blank\" id=\"26042815 \">26042815 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 83316 Version 79.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F13841863\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F13853113\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F13853122\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F13841927\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F13841865\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13853123\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F13841896\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13853114\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13841884\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F13841879\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13841880\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26023254\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13841889\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F13841887\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F13841894\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F13841873\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13841874\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13853124\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F13841897\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F13841899\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F13841930\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F13841933\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/83316|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ivermectin-systemic-drug-information\" class=\"drug drug_general\">Ivermectin (systemic): Drug information</a></li><li><a href=\"topic.htm?path=ivermectin-systemic-patient-drug-information\" class=\"drug drug_patient\">Ivermectin (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}